Evidence map›Paper›PMID 35524156›Full record

ArticleNature communications2022

Regulated IRE1α-dependent decay (RIDD)-mediated reprograming of lipid metabolism in cancer.

Aitor Almanza, Katarzyna Mnich, Arnaud Blomme, Claire M Robinson, Giovanny Rodriguez-Blanco, Sylwia Kierszniowska, Eoghan P McGrath, Matthieu Le Gallo, Eleftherios Pilalis, Johannes V Swinnen and 4 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 1 pooled it
8.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 5 countries.

Aitor Almanza *Apoptosis Research Centre, National University of Ireland, Galway, H91 W2TY, Ireland.
Katarzyna Mnich *Apoptosis Research Centre, National University of Ireland, Galway, H91 W2TY, Ireland.ORCID 0000-0003-2137-9163
Arnaud BlommeCRUK Beatson Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK.ORCID 0000-0003-4183-8726
Claire M RobinsonApoptosis Research Centre, National University of Ireland, Galway, H91 W2TY, Ireland.
Giovanny Rodriguez-BlancoCRUK Beatson Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK.ORCID 0000-0002-7154-7244
Sylwia KierszniowskametaSysX GmbH, 14476, PotsdGarscube Estateam-Golm, Germany.
Eoghan P McGrathApoptosis Research Centre, National University of Ireland, Galway, H91 W2TY, Ireland.
Matthieu Le GalloInserm U1242, University of Rennes, Rennes, France.
Eleftherios Pilalise-NIOS Applications PC, 25 Alexandros Pantou str., 17671, Kallithea, Greece.ORCID 0000-0002-5253-5256
Johannes V SwinnenDepartment of Oncology, Laboratory of Lipid Metabolism and Cancer, KU Leuven Cancer Institute, Leuven, Belgium.ORCID 0000-0002-7720-5077
Aristotelis Chatziioannoue-NIOS Applications PC, 25 Alexandros Pantou str., 17671, Kallithea, Greece.
Eric ChevetInserm U1242, University of Rennes, Rennes, France.ORCID 0000-0001-5855-4522
Adrienne M GormanApoptosis Research Centre, National University of Ireland, Galway, H91 W2TY, Ireland.ORCID 0000-0002-6068-0058
Afshin SamaliApoptosis Research Centre, National University of Ireland, Galway, H91 W2TY, Ireland. afshin.samali@nuigalway.ie.ORCID 0000-0002-8610-8375
Ollscoil na Gaillimhe – University of Galway · IECancer Research UK Scotland Institute · GBInserm · FRAcademy of Athens · GRNational University of Ireland · IEVIB-KU Leuven Center for Cancer Biology · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IRE1α is constitutively active in several cancers and can contribute to cancer progression. Activated IRE1α cleaves XBP1 mRNA, a key step in production of the transcription factor XBP1s. In addition, IRE1α cleaves select mRNAs through regulated IRE1α-dependent decay (RIDD). Accumulating evidence implicates IRE1α in the regulation of lipid metabolism. However, the roles of XBP1s and RIDD in this process remain ill-defined. In this study, transcriptome and lipidome profiling of triple negative breast cancer cells subjected to pharmacological inhibition of IRE1α reveals changes in lipid metabolism genes associated with accumulation of triacylglycerols (TAGs). We identify DGAT2 mRNA, encoding the rate-limiting enzyme in TAG biosynthesis, as a RIDD target. Inhibition of IRE1α, leads to DGAT2-dependent accumulation of TAGs in lipid droplets and sensitizes cells to nutritional stress, which is rescued by treatment with the DGAT2 inhibitor PF-06424439. Our results highlight the importance of IRE1α RIDD activity in reprograming cellular lipid metabolism.

Indexed as

EndoribonucleasesLipid MetabolismNeoplasmsProtein Serine-Threonine KinasesEndoplasmic Reticulum StressHumansRNA, MessengerTranscription FactorsX-Box Binding Protein 1EndoribonucleasesERN1 protein, humanProtein Serine-Threonine KinasesRNA, MessengerTranscription FactorsX-Box Binding Protein 1

Identifiers

PMID35524156
PMCPMC9076827
OpenAlexW4229082167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.